Mark Schoenberg Sells 871 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 871 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total value of $37,383.32. Following the completion of the transaction, the insider directly owned 59,882 shares in the company, valued at approximately $2,570,135.44. This trade represents a 1.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, August 20th, Mark Schoenberg sold 60,677 shares of Urogen Pharma stock. The shares were sold at an average price of $47.05, for a total value of $2,854,852.85.
• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $40.00, for a total value of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total value of $350,100.00.

Urogen Pharma Trading Down 6.1%

URGN opened at $42.24 on Friday. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81. The business’s fifty day simple moving average is $43.24 and its 200-day simple moving average is $31.46. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -21.33 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. On average, equities research analysts predict that Urogen Pharma will post -0.2 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on URGN. UBS Group restated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. TD Cowen increased their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Oppenheimer lifted their price objective on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Guggenheim boosted their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a report on Wednesday, July 15th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Urogen Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $52.38.

Institutional Trading of Urogen Pharma

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC grew its position in shares of Urogen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock worth $1,262,000 after buying an additional 88,577 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares in the last quarter. Jane Street Group LLC lifted its position in Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after acquiring an additional 24,839 shares during the last quarter. Cetera Investment Advisers purchased a new stake in Urogen Pharma during the second quarter valued at approximately $361,000. Finally, JPMorgan Chase & Co. boosted its stake in Urogen Pharma by 5.2% in the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock valued at $5,348,000 after acquiring an additional 19,405 shares in the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.